Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.
about
FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaBMolecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agentsIdentification of new peptide ligands for epidermal growth factor receptor using phage display and computationally modeling their mode of binding.Revisiting the role of antiandrogen strategies in ovarian cancer.Differential regulation of transcription factors by location-specific EGF receptor signaling via a spatio-temporal interplay of ERK activation.In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common featuresThe emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutationsEpitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope.Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRASCetuximab and biomarkers in non-small-cell lung carcinomaA complex of α6 integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties.Rationale for the design of an oncology trial using a generic targeted therapy multi‑drug regimen for NSCLC patients without treatment options (Review)Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.Receptor-based targeting of therapeutics.High Boron-loaded DNA-Oligomers as Potential Boron Neutron Capture Therapy and Antisense Oligonucleotide Dual-Action Anticancer Agents.The tyrphostin AG1478 augments oridonin-induced A431 cell apoptosis by blockage of JNK MAPK and enhancement of oxidative stress.Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective AnalysisAliphatic acetogenin constituents of avocado fruits inhibit human oral cancer cell proliferation by targeting the EGFR/RAS/RAF/MEK/ERK1/2 pathway.Helioxanthin suppresses the cross talk of COX-2/PGE2 and EGFR/ERK pathway to inhibit Arecoline-induced Oral Cancer Cell (T28) proliferation and blocks tumor growth in xenografted nude mice.Genomic compartmentalization of gene families encoding core components of metazoan signaling systems.Analysis of the main active ingredients and bioactivities of essential oil from Osmanthus fragrans Var. thunbergii using a complex network approach.Overexpression of CXCR4 promotes invasion and migration of non-small cell lung cancer via EGFR and MMP-9.Erlotinib-associated dermatological toxicity.
P2860
Q24300387-55D5C9A0-18BF-4465-B916-1525679EE3FEQ28304646-1FCF58A9-93EF-4CE4-A60A-71E39FF7ABECQ34089704-5F037D57-ED09-4F9B-8082-32655E66532CQ34219464-4716F576-6A73-474A-9F7E-4D17F3744CCBQ34415844-54F7E0F8-9554-4F67-80A8-72F833497F2BQ34976925-748279A8-938A-4013-92D2-CEEEF225BD8AQ35076292-38005ED4-0B99-4263-8EC5-D29A35064B92Q35214496-87ADC484-305A-43BC-8BA0-2E6454691B29Q35946356-88B0CF9B-0B98-4578-B9BF-15EC13AAFF99Q36040606-DCD1B149-9D69-4D91-8FF2-A7706D57DF37Q36171281-38BF8F5E-8CBE-4D01-AD58-F44431C88C5CQ36389313-A1ED7D80-4082-4943-AB6C-2E84A8878148Q36517741-16EA3E35-7DD6-4555-9BF6-C7E831F3B90AQ37098747-AFB4FF6F-F18D-4B74-9EAE-EFC05E2D5AC5Q37260992-F1331093-911D-4FE8-9FF0-0A196F497271Q38008456-A74C744C-0465-44DA-BB0A-7F1487D41E4AQ38084739-383C7B8B-3B30-46AD-A60E-7F046889094CQ38287453-595C507D-844A-4E38-8F3C-27AC282764A2Q39299745-B7FA55FA-7056-401F-ABCA-81019AC36439Q41412426-DC41ECBE-8179-470A-80D5-4E3333E66913Q41461334-E8268AF5-46BF-4BE4-8B23-469F644CA93CQ42139652-521EB1C7-E371-4892-B746-636BE8333168Q42700365-EF810184-BE46-48B6-B27F-09BBD23C38BAQ44255021-B7C4385B-E7E5-4ADE-A879-1653CC9F826AQ47158855-319C7C9D-6299-4F78-9ECD-AD15BB90B157Q47654279-67D885D0-E0D0-42A9-BC17-76AB0C08595AQ54487599-36879A13-038D-40C6-91E7-5D5238E61668
P2860
Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Epidermal growth factor recept ...... R-targeted anticancer therapy.
@ast
Epidermal growth factor recept ...... R-targeted anticancer therapy.
@en
type
label
Epidermal growth factor recept ...... R-targeted anticancer therapy.
@ast
Epidermal growth factor recept ...... R-targeted anticancer therapy.
@en
prefLabel
Epidermal growth factor recept ...... R-targeted anticancer therapy.
@ast
Epidermal growth factor recept ...... R-targeted anticancer therapy.
@en
P2860
P1433
P1476
Epidermal growth factor recept ...... R-targeted anticancer therapy.
@en
P2093
Isamu Okamoto
P2860
P304
P356
10.1111/J.1742-4658.2009.07449.X
P407
P577
2009-11-18T00:00:00Z